Association between red cell distribution width and response to methotrexate in rheumatoid arthritis

Area of Science:

• Rheumatology
• Clinical Immunology
• Hematology

Background:

• Red cell distribution width (RDW) is increasingly recognized as an unconventional biomarker for systemic inflammation.
• Its potential role in predicting treatment outcomes in autoimmune diseases like rheumatoid arthritis (RA) requires further investigation.

Purpose of the Study:

• To investigate the association between baseline RDW and treatment response in RA patients receiving methotrexate (MTX).
• To evaluate changes in RDW following MTX initiation and their correlation with treatment effectiveness.

Main Methods:

• Retrospective analysis of 82 RA patients treated with MTX.
• Assessment of baseline RDW, disease activity scores, and inflammatory markers.
• Monitoring of RDW changes and European League Against Rheumatism (EULAR) response at three months.

Main Results:

• Lower baseline RDW was associated with a higher likelihood of good EULAR response at three months (p=0.009).
• MTX treatment led to a significant increase in RDW (p<0.0001).
• The magnitude of RDW increase correlated positively with the degree of treatment response, being greatest in patients with good EULAR response (p=0.03).

Conclusions:

• RDW serves as a potent predictor of early treatment response to MTX in RA patients.
• The observed increase in RDW post-MTX initiation, paralleling treatment response, suggests its utility as a marker for MTX effectiveness.